A Cell Press partner journal
See the unseen. Change the unchanged.
The Innovation ¡ª published by Cell Press in partnership with members of the Youth
Innovation Promotion Association (YIPA),a part of the Chinese Academy of
Sciences¡ªis a new broad-scope, open access journal publishing basic and applied
research that has impact for the benefit of society.
On the cover: The sun not only breeds all life, but also brings inexhaustible clean energy to the earth. The development of flexible photovoltaic technology, represented by flexible perovskite solar cells, frees the energy production from the constraints of traditional centralized photovoltaic application scenarios. From spacecraft and curved photovoltaics to wearable devices and IoT sensors, the combination of flexible photovoltaics and advanced technology will realize a more flexible, convenient and imaginative collection and utilization of solar energy, contributing to a more intelligent and sustainable human society.
  Related comments
Add comment (English only)
Name*:  
E-mail:  
Telephone:  
Code:    
Comments*:
Position: Home > issue > November 08, 2022 Volume 3, Issue 6
The First Chinese Oral Anti-COVID-19 Drug Azvudine Launched
Category:   News & Buzz   Download:  PDF  Figure  Endnote
Author: Bin Yu, Junbiao Chang

g2.jpg

Mechanism of Azvudine against SARS-CoV-2


Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) at the end of 2019, thousands of SARS-CoV-2 mutations have been increasingly observed. The virus epidemic has posed unprecedented challenges to global public health. As of September 6, 2022, over 603 million confirmed cases and about 6.48 million deaths worldwide have been reported to the World Health Organization (WHO). The development of novel antivirals capable of treating SARS-CoV-2 infections has been a central focus of current research. To cope with the current novel coronavirus pneumonia (COVID-19) epidemic, the National Medical Products Administration (NMPA) granted conditional authorization for Azvudine developed by us to be used to treat COVID-19 on July 25, 2022, being the first domestic oral antiviral agent approved in China.





Host
ISSN 2666-6758
Publishing partner
Journal links
 
Academic co-partner
SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS
INSTITUTE OF MICROBIOLOGY, CAS
XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
 
Collections

Air Pollution
Astronomy
Cancer
Chemistry
COVID-19
Environment Changes
Geoscience
Life Sciences
Materials
Medicine
Physics
ScienceX / Interdiscipline

 
Stay connected
  the.innovation.journal
  the.innovation.journal
  The Innovation
  TheInnovation´´ÐÂ
  TheInnovation´´ÐÂ
  The_Innovation
  office@the-innovation.org
  Official£º
Astronomy£º
Chemistry£º
Geoscience£º
Informatics£º
Life Science£º
Management£º
Materials£º
Medicine£º
Physics£º
ScienceX£º

@The_InnovationJ
@Innov_Astronomy
@InnovationChem
@Innov_Geosci
@Innov_inf
@Innov_LifeSci
@Innov_MGT
@Innov_Materials
@Innov_Medicine
@InnovationPhys
@Innov_ScienceX

  Copyright © 2019-2022 the-innovation.org All Rights Reserved